Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership
|
GSK plc (GSK)
| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 09/16/2022 | Theravance Biopharma, Inc. | TBPH | Other (disposition) | Ordinary Shares | 9.6M | $9.75 | $94M | By Corporation | 09/16/2022 |
| 09/16/2022 | Theravance Biopharma, Inc. | TBPH | Other (acquisition) | Exchangeable Senior Notes due 2023 | 0 | $29.07 | $0 | See Footnote | 09/16/2022 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Common Stock | 1.5k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Common Stock | 13k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Common Stock | 14.9k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Common Stock | 8.4k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Common Stock | 27.3k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Common Stock | 635.6k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Purchase | Common Stock | 275k | $18.00 | $5M | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Series B-2 Preferred Stock | 59.5k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Series C-2 Preferred Stock | 513.3k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Series D-2 Preferred Stock | 589.9k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Series E-2 Preferred Stock | 331.4k | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Series F-2 Preferred Stock | 1.1M | $0.00 | $0 | See Footnote | 07/02/2021 |
| 07/02/2021 | CVRx, Inc. | CVRX | Conversion | Series G Preferred Stock | 10.1M | $0.00 | $0 | See Footnote | 07/02/2021 |
| 06/21/2021 | Lyell Immunopharma, Inc. | LYEL | Conversion | Common Stock | 30.3M | $0.00 | $0 | See Footnote | 06/21/2021 |
| 06/21/2021 | Lyell Immunopharma, Inc. | LYEL | Conversion | Series AA Preferred Stock | 30.3M | $0.00 | $0 | See Footnote | 06/21/2021 |
| 05/20/2021 | Innoviva, Inc. | INVA | Sale | Common Stock | 32M | $12.25 | $392.1M | See Footnote | 05/20/2021 |
| 02/17/2021 | Decibel Therapeutics, Inc. | DBTX | Conversion | Common Stock | 458.5k | $0.00 | $0 | See Footnote | 02/17/2021 |
| 02/17/2021 | Decibel Therapeutics, Inc. | DBTX | Conversion | Series D Preferred Stock | 1.7M | $0.00 | $0 | See Footnote | 02/17/2021 |
| 02/17/2021 | Decibel Therapeutics, Inc. | DBTX | Conversion | Common Stock | 247.3k | $0.00 | $0 | See Footnote | 02/17/2021 |
| 02/17/2021 | Decibel Therapeutics, Inc. | DBTX | Conversion | Common Stock | 327.9k | $0.00 | $0 | See Footnote | 02/17/2021 |
| 02/17/2021 | Decibel Therapeutics, Inc. | DBTX | Purchase | Common Stock | 150k | $18.00 | $2.7M | See Footnote | 02/17/2021 |
| 02/17/2021 | Decibel Therapeutics, Inc. | DBTX | Conversion | Series A Preferred Stock | 7.1M | $0.00 | $0 | See Footnote | 02/17/2021 |
| 02/17/2021 | Decibel Therapeutics, Inc. | DBTX | Conversion | Series C Preferred Stock | 3.1M | $0.00 | $0 | See Footnote | 02/17/2021 |
| 07/24/2020 | GENOCEA BIOSCIENCES, INC. | GNCA | Purchase | Common Stock | 1.3M | $2.25 | $2.8M | See Footnote | 07/24/2020 |
| 07/24/2020 | GENOCEA BIOSCIENCES, INC. | GNCA | Purchase | Warrant | 1.3M | $2.25 | $2.8M | See Footnote | 07/24/2020 |
| 07/21/2020 | Pandion Therapeutics, Inc. | PAND | Conversion | Common Stock | 1.5M | $0.00 | $0 | See Footnote | 07/17/2020 |
| 07/21/2020 | Pandion Therapeutics, Inc. | PAND | Conversion | Common Stock | 348.5k | $0.00 | $0 | See Footnote | 07/17/2020 |
| 07/21/2020 | Pandion Therapeutics, Inc. | PAND | Purchase | Common Stock | 361.1k | $18.00 | $6.5M | See Footnote | 07/17/2020 |
| 07/21/2020 | Pandion Therapeutics, Inc. | PAND | Conversion | Series A Preferred Stock | 7.8M | $0.00 | $0 | See Footnote | 07/17/2020 |
| 07/21/2020 | Pandion Therapeutics, Inc. | PAND | Conversion | Series B Preferred Stock | 1.8M | $0.00 | $0 | See Footnote | 07/17/2020 |
| 07/17/2020 | Pandion Therapeutics, Inc. | PAND | Grant | Stock Option (right to buy) | 14k | $18.00 | $251.9k | See Footnote | 07/17/2020 |
| 07/15/2020 | BICYCLE THERAPEUTICS plc | BCYC | Sale | Common Stock | 3.1k | $19.40 | $59.5k | See Footnote | 07/14/2020 |
| 07/15/2020 | BICYCLE THERAPEUTICS plc | BCYC | Sale | Common Stock | 78 | $19.25 | $1.5k | See Footnote | 07/14/2020 |
|
|